---
title: EGFR CART Cells for Patients With Metastatic Colorectal Cancer
nct_id: NCT03152435
overall_status: UNKNOWN
phase: PHASE1, PHASE2
sponsor: "Shenzhen Second People's Hospital"
study_type: INTERVENTIONAL
primary_condition: EGFR-positive Colorectal Cancer
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03152435.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03152435"
ct_last_update_post_date: 2017-08-16
last_seen_at: "2026-05-12T07:34:41.812Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# EGFR CART Cells for Patients With Metastatic Colorectal Cancer

**Official Title:** Phase I/II Study of EGFR CART Cells for Patients With Metastatic Colorectal Cancer.

**NCT ID:** [NCT03152435](https://clinicaltrials.gov/study/NCT03152435)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** PHASE1, PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 20
- **Lead Sponsor:** Shenzhen Second People's Hospital
- **Collaborators:** The Beijing Pregene Science and Technology Company, Ltd.
- **Conditions:** EGFR-positive Colorectal Cancer
- **Start Date:** 2017-06-15
- **Completion Date:** 2019-12
- **CT.gov Last Update:** 2017-08-16

## Brief Summary

This is a clinical study to observe the maximum tolerated dose (MTD) and the safety and feasibility of chimeric antigen receptor EGFR (EGFR CART) cells in metastatic patients with colorectal cancer.

## Detailed Description

This is a study for the patients with colorectal cancer. Maximum tolerated dose climbing test is expected into the group of 9 cases of patients. And Phase II expected into the group of 11 subjects, selected the above safe dose, carrying out a research into the clinical effectiveness. Subjects will be collected their T cells and modify them, the modification is a genetic change, that EGFR:4-1BB:CD28:CD3 modified T cells, in order to tells the T cells to recognize their target tumor cells and potentially kill them, but not other normal cells in the subject's body. The CART cells will then be expanded in vitro and then administered to subjects. The purpose of this study is observe the MTD and to assess the safety and feasibility of CART cells in the patients with metastatic colorectal cancer.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 70 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* 1\. Patients must be 18 years to 70 years;
* 2\. Clinical diagnosis of EGFR positive for patients with metastatic colorectal cancer;
* 3\. Patients must have a KPS of \>80, expected survival \> 3 months;
* 4\. Patients must have at least one measurable lesions;
* 5\. Recently did not use glucocorticoid;
* 6\. Patients must have evidence of adequate hepatic and renal function as evidenced by the following laboratory parameters: WBC ≥ 4.0×109/L, Hb ≥90 g/L, PLT ≥100×109/L）; AST ≤2.5ULN，ALT ≤ 2.5ULN; Cr≤ 3ULN; TBIL≤ 3ULN，
* 7\. Patients must have a good heart function (LVEF\>50%) ;
* 8\. Patients must be willing to practice birth control during and for three months following treatment.NOTE:female participants of reproductive potential must have a negative serum pregnancy test, and willing to practice birth control during and for three months following treatment；
* 9\. Patients must be willing to sign an informed consent.

Exclusion Criteria:

* 1\. Patients with other cancer history;
* 2\. Patients allergic to cetuximab;
* 3\. Patients with severe bronchitis, bronchial asthma, or severs pneumonia;
* 4\. Patients with uncontrolled active infections (bacteria, viruses or fungi infection) ;
* 5\. Patients with acute and chronic GVHD (graft versus host disease)
* 6\. Patients with severe autoimmune diseases;
* 7\. Previously treatment with T cell inhibitors (cyclophosphamide, FK506);
* 8\. Patients with active hepatitis B or hepatitis C infection, HIV infection, syphilis serology reaction positive;
* 9\. Patients who are participating or participated any other clinical research in the past 1 months;
* 10\. Pregnant and/or lactating women will be excluded;
```

## Arms

- **anti-tumor response of CART-EGFR** (EXPERIMENTAL)

## Interventions

- **EGFR CART** (BIOLOGICAL) — EGFR CART cells will be administered using a split dose on day0 (10%),1(30%), and 2(60%).

## Primary Outcomes

- **Occurrence of study related adverse events as assessed by CTCAE v4.0** _(time frame: 24 weeks)_

## Secondary Outcomes

- **Anti-tumor responses to EGFR CART cells in vivo.** _(time frame: 24 weeks)_
- **Determine duration of in vivo survival of EGFR CART .** _(time frame: 1 year)_

## Locations (1)

- The Second People's Hospital of Shenzhen, Shenzhen, Guangdong, China — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.the second people's hospital of shenzhen|shenzhen|guangdong|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03152435.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03152435*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*